SCHEMBL7659979

SCHEMBL7659979

CC(=O)Nc1ccc(Br)c(Br)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
MAPT P10636 4/20 0.52
ALDH1A1 P00352 4/20 0.52
TDP1 Q9NUW8 1/20 0.52
CA12 O43570 1/20 0.52
BRD4 O60885 1/20 0.52
NR1I2 O75469 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MB P02144 1/20 0.52
CYP1A1 P04798 1/20 0.52
CA3 P07451 1/20 0.52
CYP3A4 P08684 1/20 0.52
RARG P13631 1/20 0.52
TSHR P16473 1/20 0.52
ALOX5AP P20292 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL879793 0.84 PKM (0.59) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL11639507 0.84 RXFP1 (0.51) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL527724 0.84 IDO1 (0.64) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL30230948 0.84 IDO1 (0.64) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL11638580 0.84 CA1 (0.60) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL2556808 0.84 SMN1; SMN2 (0.57) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL31094956 0.84 SMN1; SMN2 (0.57) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL693623 0.84 PKM (0.54) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL23885336 0.82 HDAC1 (0.54) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL4606482 0.82 TDP1 (0.55) HTTSMN1; SMN2L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399642-B2 TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2002-06-04 US disclosed
US-20010009919-A1 Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2001-07-26 US disclosed
US-6221892-B1 Heterocyclic topoisomerase poisons THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS 2001-04-24 US disclosed
EP-1054870-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-11-29 EP disclosed
US-6063801-A Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-05-16 US disclosed
WO-1999041241-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-08-19 WO disclosed
US-4355030-A Antiviral combinations ELI LILLY AND COMPANY (US) 1982-10-19 US disclosed
US-4289773-A ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXOQUINOXALINE CARBOXYLATE AND A HINDERED AMINE ELI LILLY AND COMPANY (US) 1981-09-15 US disclosed
EP-0029658-A1 Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them ELI LILLY AND COMPANY (US) 1981-06-03 EP disclosed
US-4271162-A ETHYL 6,7-DICHLORO-3,4-DIHYDRO-3-ONOQUINOXALINE CARBOXYLATE AND 1-AMINOADAMANTANE ELI LILLY AND COMPANY (US) 1981-06-02 US disclosed
US-4264600-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-04-28 US disclosed
US-4252954-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US disclosed
EP-0020836-A1 Antiviral combinations ELI LILLY AND COMPANY (US) 1981-01-07 EP disclosed
US-4210647-A INFLUENZA VIRUS, ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXO-2-QUINOXALINECARBOXYLATE, 1-AMINOADAMANTANE ELI LILLY AND COMPANY (US) 1980-07-01 US disclosed
EP-0010426-A1 Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof ELI LILLY AND COMPANY (US) 1980-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009919-A1 Heterocyclic topoisomerase poisons TOP1, TOP2A, TOP2B HTT 1871/4885SMN1; SMN2 1095/4885L3MBTL1 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.